Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs TransMedics Group Inc (TMDX) Price & Performance

iShares 1 3 Year Treasury Bond ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

iShares 1 3 Year Treasury Bond ETF vs TransMedics Group Inc — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.65, while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: TransMedics Group Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

SHYTMDX
Sector
Fixed IncomeTechnology
52-Week High
$83.18$150.42
52-Week Low
$81.59$61.99
Market Cap
$3.06B
Enterprise Value
$3.46B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 1 3 Year Treasury Bond ETF

SHY is currently trading at $81.66, showing minimal daily movement with a slight decline of 0.04%. The technical picture appears bearish with moving averages signaling caution, though oscillators suggest some buying opportunity. Recent corporate actions include consistent dividend payments scheduled through mid-2026, providing income stability for shareholders amid market volatility.

The outlook for SHY reflects mixed signals with technical indicators showing bearish momentum but potential oversold conditions. Investment opportunities include dividend income stability, while risks center on broader bond market volatility and interest rate sensitivity. The stock faces headwinds from rising Treasury yields and inflation concerns that could pressure fixed-income investments.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.

The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX